We provide you with 20 years of free, institutional-grade data for CSTL stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CSTL. Explore the full financial landscape of CSTL stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-04 | 1447362 | CSTL | 10-Q | Url |
| 2025-05-05 | 1447362 | CSTL | 10-Q | Url |
| 2025-02-27 | 1447362 | CSTL | 10-K | Url |
| 2024-11-04 | 1447362 | CSTL | 10-Q | Url |
| 2024-08-05 | 1447362 | CSTL | 10-Q | Url |
| 2024-05-02 | 1447362 | CSTL | 10-Q | Url |
| 2024-02-28 | 1447362 | CSTL | 10-K | Url |
| 2023-11-02 | 1447362 | CSTL | 10-Q | Url |
| 2023-08-02 | 1447362 | CSTL | 10-Q | Url |
| 2023-05-03 | 1447362 | CSTL | 10-Q | Url |
| 2023-02-28 | 1447362 | CSTL | 10-K | Url |
| 2022-11-02 | 1447362 | CSTL | 10-Q | Url |
| 2022-08-08 | 1447362 | CSTL | 10-Q | Url |
| 2022-05-09 | 1447362 | CSTL | 10-Q | Url |
| 2022-02-28 | 1447362 | CSTL | 10-K | Url |
| 2021-11-08 | 1447362 | CSTL | 10-Q | Url |
| 2021-08-09 | 1447362 | CSTL | 10-Q | Url |
| 2021-05-10 | 1447362 | CSTL | 10-Q | Url |
| 2021-03-11 | 1447362 | CSTL | 10-K | Url |
| 2020-11-09 | 1447362 | CSTL | 10-Q | Url |
| 2020-08-10 | 1447362 | CSTL | 10-Q | Url |
| 2020-06-22 | 1447362 | CSTL | S-1 | Url |
| 2020-05-11 | 1447362 | CSTL | 10-Q | Url |
| 2020-03-10 | 1447362 | CSTL | 10-K | Url |
| 2019-11-12 | 1447362 | CSTL | 10-Q | Url |
| 2019-09-03 | 1447362 | CSTL | 10-Q | Url |
| 2019-06-26 | 1447362 | CSTL | S-1 | Url |
Castle Biosciences, Inc(NASDAQ:CSTL) 
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melano...
Website: http://www.castlebiosciences.com
Founded: 2007
IPO Price: $16 (Jul 25, 2019)
Full Time Employees: 133
CEO: Derek J. Maetzold
Sector: Healthcare
Industry: Diagnostics & Research
The information provided in this report about CSTL stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.